Our data strongly support the concept that increasing the expression of the SEC23A gene may prove a novel therapeutic strategy for CDA II not only for the treatment of anemia but also of the iron overload that remains the most harmful complication of this condition. Here, SEC23A is linked to anemia (phenotype).